Welcome to our dedicated page for QUEST DIAGNOSTICS SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics announced that its board of directors has elected Timothy (Tim) Wentworth, former chief executive officer of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, as a director. Including Mr. Wentworth, the board now has eleven members.
The board also appointed him to the Compensation and Leadership Development Committee and the Quality and Compliance Committee and determined he qualifies as an independent director under New York Stock Exchange standards and the company’s governance guidelines. As part of standard non-employee director compensation, he received a prorated one-time restricted share unit grant valued at approximately $43,000.
Quest highlights Mr. Wentworth’s extensive leadership background running large healthcare and consumer-focused organizations, including guiding Express Scripts into a Fortune 25 company with more than $100 billion in revenues before its acquisition by Cigna, as well as senior roles at Mary Kay and PepsiCo. The company’s press release with additional background is furnished as an exhibit.
WENTWORTH TIMOTHY C reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Timothy C. Wentworth received an equity award of 215 shares of Common Stock in the form of restricted stock units. The grant was reported at a price of $0.00 per share as compensation, not a market purchase. Following this award, his directly owned position reported in this filing is 215 shares.
QUEST DIAGNOSTICS INC director Timothy C. Wentworth filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as an insider of the company. The filing does not report any stock purchases, sales, option exercises, gifts, or other transactions.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported two stock transactions involving the company’s common stock. On a performance stock award settlement, he acquired 13,947 shares at $204.86 per share, increasing his direct holdings to 40,988 shares.
On the same date, 7,720 shares were disposed of at $204.86 per share, delivered back to Quest Diagnostics solely to cover tax withholding obligations related to that performance share award, leaving him with 33,268 directly owned shares after the tax-related disposition.
Quest Diagnostics EVP Catherine T. Doherty reported multiple stock transactions involving company common shares. On March 4, 2026, she acquired 11,364 shares as a performance stock award at $204.86 per share, approved under Rule 16b-3(d).
On the same date, 5,806 shares were disposed of back to Quest Diagnostics solely to cover tax withholding obligations from that award at $204.86 per share. On March 5, 2026, she executed an open-market sale of 5,558 shares at an average price of $206.21 per share pursuant to a pre-established Rule 10b5-1 sales plan.
After these transactions, she directly owned 67,122 common shares. She also indirectly held 4,502 shares through company 401(k) and supplemental deferred compensation plans, with amounts based on plan account balances and the market price of Quest Diagnostics stock.
Quest Diagnostics senior executive Mark E. Delaney reported stock-based compensation activity involving company common stock. On March 4, 2026, he acquired 5,682 shares of Quest Diagnostics common stock at a value of $204.86 per share through the settlement of a performance stock award approved under Rule 16b-3(d).
On the same date, 2,326 shares of common stock were disposed of back to Quest Diagnostics solely to cover tax withholding obligations related to that award, as indicated in the footnotes. Following these transactions, Delaney directly owned 11,864 shares of Quest Diagnostics common stock.
Quest Diagnostics senior executive Michael E. Prevoznick reported several share movements in Quest Diagnostics Inc. common stock. On March 5, 2026, he completed an open-market sale of 3,878 shares at $206.21 per share under a pre-arranged Rule 10b5-1 sales plan, leaving him with 37,557 directly held shares after that trade.
On March 4, 2026, he received a grant or award of 7,232 shares at a reference price of $204.86 per share, issued in settlement of a performance stock award that had been approved under Rule 16b-3(d). Also on that date, 3,354 shares were disposed of back to Quest Diagnostics solely to cover tax withholding obligations from that award settlement.
Separately, the filing notes indirect ownership of 5,737 shares through the company’s 401(k) and Supplemental Deferred Compensation Plan, with these plan holdings accumulated periodically by the plan trustee.
Quest Diagnostics CEO and President J. E. Davis reported mixed equity transactions involving company stock. On a grant date of March 4, 2026, Davis acquired 51,652 shares of Quest Diagnostics common stock at a price of $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). In a related move, 26,414 shares of common stock were disposed of back to the issuer at $204.86 per share to cover tax withholding obligations from the settlement. After these transactions, Davis directly held 142,423 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president for Diagnostic Services Patrick Plewman reported a mix of stock award activity, tax-related share disposition, and an open-market sale of common stock. On March 4, he acquired 5,682 shares as a grant or award at $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). On the same date, 2,827 shares were disposed of at $204.86 per share to Quest Diagnostics to cover tax withholding obligations from that award, leaving 18,053 shares directly owned afterward. On March 5, he sold 2,855 shares of common stock in an open-market transaction at $206.21 per share under a pre-arranged Rule 10b5-1 trading plan, resulting in direct ownership of 15,198 shares.
Quest Diagnostics executive Michael J. Deppe reported offsetting equity transactions involving company stock. He acquired 1,473 shares of Quest Diagnostics common stock on a grant/award basis tied to a performance stock award, valued at $204.86 per share, increasing his holdings at that moment to 35,946 shares.
On the same date, 750 shares were disposed of back to Quest Diagnostics at $204.86 per share solely to cover tax withholding obligations arising from the settlement of that performance stock award. After the tax-withholding disposition, Deppe directly owned 35,196 shares of Quest Diagnostics common stock.